HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 - Trial NCT04566445
Access comprehensive clinical trial information for NCT04566445 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gyroscope Therapeutics Limited and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gyroscope Therapeutics Limited
Timeline & Enrollment
Phase 2
Nov 11, 2020
Oct 31, 2023
Primary Outcome
Progression of geographic atrophy
Summary
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of
 GT005 administered as a single subretinal injection in subjects with geographic atrophy
 secondary to age-related macular degeneration (AMD).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04566445
Non-Device Trial